Goodwin Procter LLP advised ImmuNext Inc. on its option and license agreement with Curis, Inc. (NASDAQ: CRIS).
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext’s lead compound, CI-8993 (formerly JNJ-61610588). CI-8993 is a clinical-stage monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA) signaling pathway.
Under the terms of the agreement with ImmuNext, Curis will make an upfront payment to ImmuNext in exchange for an option to obtain an exclusive, worldwide license to develop and commercialize ImmuNext’s anti-VISTA compounds and products containing these compounds in the field of oncology.
The Goodwin team was led by Kathleen Kean (Picture), Sarah Solomon and Sarah Stoiber.
Law Firms: Goodwin Procter;
Clients: ImmuNext Inc;